Polycystic Kidney Disease – Landscape & Forecast – Disease Landscape & Forecast
Copy/Paste the core content from the latest edited report brochure. DELETE the “Market Outlook” header from the top.
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly, in the early stages, the disease is often asymptomatic and detectable only through diagnostic imaging of the kidney to reveal cysts. The launch of Otsuka’s Jynarque / Jinarc / Samsca (tolvaptan) introduced the first disease-specific therapy for ADPKD. Several more therapies for ADPKD are in clinical trials, including Reata Pharmaceutical’s bardoxolone methyl, Galapagos’s GLPG2737, Kadmon’s tesevatinib, and Xortx Therapeutics’ oxypurinol. Some of these therapies are expected to fulfill current unmet needs in the treatment of ADPKD.
Questions answered
- What do key opinion leaders think about the emerging therapies bardoxolone methyl, GLPG2737, tesevatinib, and oxypurinol? How will emerging therapies differentiate themselves in an increasingly crowded market?
- How will the anticipated genericization of Otsuka’s Jynarque / Jinarc / Samsca affect the uptake of branded and emerging therapies?
- What effect have the discontinuations of Sanofi / Genzyme’s venglustat, Regulus Therapeutics’ RGLS-4326, and Palladio Bioscience’s lixivaptan had on the ADPKD therapy market?
- What are the key unmet needs in ADPKD, and which therapies likely to fulfill them?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement:
Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Polycystic Kidney Disease - Landscape & Forecast - Disease Landscape & Forecast
- Key updates
- Q4 2022
- November 2022
- Q4 2022
- Key findings
- ADPKD key findings - November 2022
- November 2022
- ADPKD key findings - November 2022
- Market outlook
- Key findings
- Market share of drug classes for ADPKD: 2021
- Market share of drug classes for ADPKD: 2031
- ADPKD SWOT analysis
- Market drivers and constraints
- What factors are driving the market for ADPKD?
- What factors are constraining the market for ADPKD?
- Annual sales for total ADPKD by progression rate segments: 2021-2031
- Annual sales of drug classes for total ADPKD: 2021-2031
- Annual patient share of key drug classes for ADPKD rapid progressors or at risk of rapid progression forms
- Annual patient share of key drug classes for ADPKD intermediate/ slow progression forms
- Drug-type-specific trends
- Patient share of disease-modifying therapies for ADPKD in the major markets: 2021-2031
- Market sales of disease-modifying therapies for ADPKD in the major markets: 2021-2031
- Patient share of disease-modifying therapies for ADPKD in the United States: 2021-2031
- Market sales of disease-modifying therapies for ADPKD in the United States: 2021-2031
- Patient share of disease-modifying therapies for ADPKD in Europe: 2021-2031
- Market sales of disease-modifying therapies for ADPKD in Europe: 2021-2031
- Patient share of disease-modifying therapies for ADPKD in Japan: 2021-2031
- Market sales of disease-modifying therapies for ADPKD in Japan: 2021-2031
- Annual patient share of antihypertensive therapies for ADPKD in the major markets: 2021-2031
- Annual sales of antihypertensive therapies for ADPKD in the major markets: 2021-2031
- Annual patient share of antihypertensive therapies for ADPKD in the United States: 2021-2031
- Annual patient share of antihypertensive therapies for ADPKD in Europe: 2021-2031
- Annual patient share of antihypertensive therapies for ADPKD in Japan: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Etiology
- Risk factors for ADPKD
- Pathophysiology
- Diagnosis
- Disease progression
- ADPKD classification based on CKD stage
- ADPKD classification based on progression rate assessed by Mayo Clinic imaging classification
- Key pathways and drug targets
- Drug targets
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition, methods, and sources used
- Diagnosed prevalent cases of ADPKD in the major pharmaceutical markets: 2021-2031
- Disease definition, methods, and sources used
- Diagnosed prevalent cases of ADPKD in the major pharmaceutical markets by disease confirmation status: 2021-2031
- Drug-treated cases of ADPKD in the major pharmaceutical markets: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for ADPKD
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for ADPKD
- Current treatments used for ADPKD
- Market events impacting the use of key current therapies for ADPKD
- Advantages and disadvantages of tolvaptan
- Key results from select clinical trials investigating tolvaptan for the treatment of ADPKD
- Key ongoing clinical trials of tolvaptan in the treatment of ADPKD
- Expert insight: tolvaptan
- RAAS inhibitors
- Advantages and disadvantages of RAAS inhibitors
- Key results from select clinical trials investigating RAAS inhibitors for the treatment of ADPKD
- Expert insight: RAAS inhibitors
- CCBs and diuretics
- Expert insight: other antihypertensive drug classes
- Medical practice
- Overview
- Factors influencing drug selection in ADPKD
- Treatment decision tree for ADPKD: United States
- Treatment decision tree for ADPKD: Europe
- Treatment decision tree for ADPKD: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in ADPKD
- Top unmet needs in ADPKD: current and future attainment
- Expert insight: unmet need in ADPKD
- Drug pipeline
- Pipeline
- Regulatory milestones
- Indication comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for ADPKD
- Estimated launch dates of key emerging therapies for the treatment of ADPKD
- Key results of select clinical trials investigating bardoxolone methyl for the treatment of ADPKD
- Key ongoing clinical trials of bardoxolone methyl in the treatment of ADPKD
- Analysis of the clinical development program for bardoxolone methyl
- Expert insight: bardoxolone methyl
- Expectations for launch and sales opportunity of bardoxolone methyl in ADPKD
- Expert insight: somatostatin analogues
- Expert insight: pravastatin sodium
- Expert insight: metformin
- Key results of select clinical trials investigating tesevatinib for the treatment of ADPKD
- Key ongoing clinical trials of tesevatinib in the treatment of ADPKD
- Analysis of the clinical development program for tesevatinib
- Expert insight: tesevatinib
- Expectations for launch and sales opportunity of tesevatinib in ADPKD
- Key results of select clinical trials investigating GLPG2737 for the treatment of ADPKD
- Key ongoing clinical trials of GLPG2737 in the treatment of ADPKD
- Analysis of the clinical development program for GLPG2737
- Expert insight: GLPG2737
- Expectations for launch and sales opportunity of GLPG2737 in ADPKD
- Expert insight: XRx-008 (oxypurinol)
- Early-phase pipeline analysis
- Select compounds in early-phase development for ADPKD
- Key discontinuations and failures in ADPKD
- Key discontinuations and failures
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in ADPKD: United States
- General reimbursement environment: United States
- Key market access considerations in ADPKD: EU5
- General reimbursement environment: EU5
- Key market access considerations in ADPKD: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- ADPKD bibliography
- Key updates
Laia Martínez-Carreres, M.Sc., Ph.D., Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematological Disorders. Dr. Martinez-Carreres has authored reports on polycystic kidney disease, venous thromboembolism, and atrial fibrillation. Prior to joining Clarivate, she was a clinical research project manager at Parc Taulí Hospital (Spain). She holds a Ph.D. in biomedical sciences from the University of Lausanne, where she studied the role of the cell cycle-related protein CDK4 in metabolism in the laboratory of Professor Lluis Fajas. She also holds a master’s degree in translational medicine and a bachelor’s degree in biomedical sciences, both from the University of Barcelona. Dr. Martínez-Carreres also trained as a data analyst at EADA Business School in Spain.